These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 7569499)

  • 61. Construction of group sequential designs in clinical trials on the basis of detectable treatment differences.
    Schäfer H; Müller HH
    Stat Med; 2004 May; 23(9):1413-24. PubMed ID: 15116350
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Blinded and unblinded internal pilot study designs for clinical trials with count data.
    Schneider S; Schmidli H; Friede T
    Biom J; 2013 Jul; 55(4):617-33. PubMed ID: 23703749
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Sample size re-estimation for adaptive sequential design in clinical trials.
    Gao P; Ware JH; Mehta C
    J Biopharm Stat; 2008; 18(6):1184-96. PubMed ID: 18991116
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Design and analysis issues of multiregional clinical trials with different regional primary endpoints.
    Tsou HH; Tsong Y; Chang WJ; Dong X; Hsiao CF
    J Biopharm Stat; 2012 Sep; 22(5):1051-9. PubMed ID: 22946949
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Sample size adjustment based on promising interim results and its application in confirmatory clinical trials.
    Chen YH; Li C; Lan KK
    Clin Trials; 2015 Dec; 12(6):584-95. PubMed ID: 26195615
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Sample size recalculation using conditional power.
    Denne JS
    Stat Med; 2001 Sep 15-30; 20(17-18):2645-60. PubMed ID: 11523074
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The role of the minimum clinically important difference and its impact on designing a trial.
    Chuang-Stein C; Kirby S; Hirsch I; Atkinson G
    Pharm Stat; 2011; 10(3):250-6. PubMed ID: 20936625
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Value of information methods to design a clinical trial in a small population to optimise a health economic utility function.
    Pearce M; Hee SW; Madan J; Posch M; Day S; Miller F; Zohar S; Stallard N
    BMC Med Res Methodol; 2018 Feb; 18(1):20. PubMed ID: 29422021
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Pilot and Repeat Trials as Development Tools Associated with Demonstration of Bioequivalence.
    Fuglsang A
    AAPS J; 2015 May; 17(3):678-83. PubMed ID: 25732246
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Calculation of tolerance limits and sample size determination for clinical trials with dichotomous outcomes.
    Zaslavsky BG
    J Biopharm Stat; 2007; 17(3):481-91. PubMed ID: 17479395
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Evaluating the adaptive performance of flexible sample size designs with treatment difference in an interval.
    Liu GF; Zhu GR; Cui L
    Stat Med; 2008 Feb; 27(4):584-96. PubMed ID: 17634972
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Statistical design and analysis of pharmacogenetic trials.
    Kelly PJ; Stallard N; Whittaker JC
    Stat Med; 2005 May; 24(10):1495-508. PubMed ID: 15706636
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Sample-size calculation and reestimation for a semiparametric analysis of recurrent event data taking robust standard errors into account.
    Ingel K; Jahn-Eimermacher A
    Biom J; 2014 Jul; 56(4):631-48. PubMed ID: 24817598
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Information-based monitoring of clinical trials.
    Tsiatis AA
    Stat Med; 2006 Oct; 25(19):3236-44; discussion 3320-5, 3326-47. PubMed ID: 16927248
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The value of information and optimal clinical trial design.
    Willan AR; Pinto EM
    Stat Med; 2005 Jun; 24(12):1791-806. PubMed ID: 15806619
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Comments on 'How conservative is Fisher's exact test? A quantitative evaluation of the two-sample comparative binomial trial' by G. G. Crans and J. J. Shuster, Statistics in Medicine 2008; 27:3598-3611.
    Martín Andrés A; Herranz Tejedor I
    Stat Med; 2009 Jan; 28(1):173-4. PubMed ID: 18825654
    [No Abstract]   [Full Text] [Related]  

  • 77. Blinded sample size recalculation in clinical trials incorporating historical data.
    Hees K; Kieser M
    Contemp Clin Trials; 2017 Dec; 63():2-7. PubMed ID: 28735110
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Sample size estimation for non-inferiority trials of time-to-event data.
    Crisp A; Curtis P
    Pharm Stat; 2008; 7(4):236-44. PubMed ID: 17583558
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Relative efficiency and sample size for cluster randomized trials with variable cluster sizes.
    You Z; Williams OD; Aban I; Kabagambe EK; Tiwari HK; Cutter G
    Clin Trials; 2011 Feb; 8(1):27-36. PubMed ID: 21163852
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Optimization of adaptive designs: efficiency evaluation.
    Menon S; Chang M
    J Biopharm Stat; 2012; 22(4):641-61. PubMed ID: 22651106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.